$ASMB
Assembly Biosciences Inc Stock $asmb

$asmb Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000114420417041660 Filed on August 09, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$2.660M	$2.359M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.180M	$3.800M	$2.940M
YoY Change	46.67%	29.25%	18.07%
% of Gross Profit
Research & Development	$10.93M	$12.13M	$7.519M
YoY Change	23.73%	61.26%	61.08%
% of Gross Profit
Depreciation & Amortization	$41.85K	$50.91K	$18.00K
YoY Change	132.48%	182.86%	12.5%
% of Gross Profit
Operating Expenses	$10.93M	$12.13M	$7.519M
YoY Change	23.73%	61.26%	61.08%
Operating Profit	-$12.45M	-$13.57M	-$10.45M
YoY Change	6.6%	29.78%	46.13%
Interest Expense	$140.0K	-$100.0K	$300.0K
YoY Change	40.0%	-133.33%	42.86%
% of Operating Profit
Other Income/Expense, Net	$142.3K	-$101.1K	$301.9K
YoY Change		-133.49%	42.94%
Pretax Income	-$12.31M	-$13.67M	-$10.15M
YoY Change	6.34%	34.63%	46.29%
Income Tax	-$35.90K	-$69.51K	$0.00
% Of Pretax Income
Net Earnings	-$12.27M	-$13.60M	-$10.15M
YoY Change	6.03%	33.95%	46.23%
Net Earnings / Revenue	-461.42%	-576.4%
Basic Earnings Per Share
Diluted Earnings Per Share	-$706.4K	-$784.3K	-$589.1K
COMMON SHARES
Basic Shares Outstanding	17.36M shares	17.35M shares	17.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$66.30M	$75.60M	$63.50M
YoY Change	13.14%	19.06%	-10.18%
Cash & Equivalents	$27.25M	$39.45M	$20.34M
Short-Term Investments	$39.10M	$36.10M	$43.20M
Other Short-Term Assets	$1.000M	$1.000M	$600.0K
YoY Change	66.67%	66.67%	-0.85%
Inventory
Prepaid Expenses
Receivables	$1.400M	$1.114M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$68.70M	$77.70M	$64.10M
YoY Change	15.85%	21.22%	-10.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$600.0K	$100.0K	$100.0K
YoY Change	500.0%	0.0%	-42.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.400M	$3.300M	$11.40M
YoY Change	-82.72%	-71.05%	-63.92%
Other Assets
YoY Change
Total Long-Term Assets	$43.66M	$45.10M	$53.10M
YoY Change	-12.45%	-15.07%	-27.63%
TOTAL ASSETS
Total Short-Term Assets	$68.70M	$77.70M	$64.10M
Total Long-Term Assets	$43.66M	$45.10M	$53.10M
Total Assets	$112.3M	$122.8M	$117.2M
YoY Change	2.93%	4.78%	-19.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$900.0K	$700.0K	$2.400M
YoY Change	-76.32%	-70.83%	84.62%
Accrued Expenses	$6.400M	$6.300M	$2.600M
YoY Change	77.78%	142.31%	177.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.20M	$12.00M	$5.000M
YoY Change	62.67%	140.0%	123.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$41.80M	$43.10M
YoY Change
Total Long-Term Liabilities	$52.96M	$43.10M	$11.60M
YoY Change	356.56%	271.55%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.20M	$12.00M	$5.000M
Total Long-Term Liabilities	$52.96M	$43.10M	$11.60M
Total Liabilities	$65.20M	$66.20M	$16.60M
YoY Change	241.36%	298.8%	19.94%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$47.10M	$56.50M	$100.6M
YoY Change
Total Liabilities & Shareholders Equity	$112.3M	$122.8M	$117.2M
YoY Change	2.93%	4.78%	-19.0%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$12.27M	-$13.60M	-$10.15M
YoY Change	6.03%	33.95%	46.23%
Depreciation, Depletion And Amortization	$41.85K	$50.91K	$18.00K
YoY Change	132.48%	182.86%	12.5%
Cash From Operating Activities	-$10.96M	-$12.35M	-$6.770M
YoY Change	39.44%	82.42%	54.21%
INVESTING ACTIVITIES
Capital Expenditures	-$500.0K	$0.00	$0.00
YoY Change	1150.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$1.010M	-$19.12M	$6.710M
YoY Change	-108.9%	-384.95%	-113.76%
Cash From Investing Activities	-$1.510M	-$19.12M	$6.710M
YoY Change	-113.34%	-384.95%	-113.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	260.0K	110.0K	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-10.96M	-12.35M	-6.770M
Cash From Investing Activities	-1.510M	-19.12M	6.710M
Cash From Financing Activities	260.0K	110.0K	0.000
Net Change In Cash	-12.21M	-31.36M	-60.00K
YoY Change	-452.89%	52166.67%	-99.86%
FREE CASH FLOW
Cash From Operating Activities	-$10.96M	-$12.35M	-$6.770M
Capital Expenditures	-$500.0K	$0.00	$0.00
Free Cash Flow	-$10.46M	-$12.35M	-$6.770M
YoY Change	33.76%	82.42%	54.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4995894	USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	611176	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	978356	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2977993	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3801541	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-232542	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	26824156	USD
CY2017Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	43074186	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22698760	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15637607	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	30540760	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	21731282	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27497080	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21731282	USD
	us-gaap	Interest Income Other InterestIncomeOther	376342	USD
	us-gaap	Interest Income Other InterestIncomeOther	935026	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-101890	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	590524	USD
	us-gaap	Net Income Loss NetIncomeLoss	-27529457	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21140758	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.59
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.23
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17305657	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17225661	shares
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27326955	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21158535	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-478232	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-344502	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-92359	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-362279	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	294861	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	344502	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12125021	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7519031	USD
CY2017Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	15926562	USD
CY2016Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	10454130	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13567251	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10454130	USD
CY2017Q2	us-gaap	Interest Income Other InterestIncomeOther	239858	USD
CY2016Q2	us-gaap	Interest Income Other InterestIncomeOther	444605	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-101126	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	301930	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-10152200	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2935099	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13472454	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10242067	USD
CY2017Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-340984	USD
CY2016Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-142675	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-31203	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	157613	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	142675	USD
	us-gaap	Depreciation Depreciation	82830	USD
	us-gaap	Depreciation Depreciation	37093	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3235908	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	22587758	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15978100	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	748058	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	0	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10877652	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6766188	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27107526	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20341338	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1680223	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1050224	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1552724	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	591742	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	367180	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-147643	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-71884	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	13460	USD
	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	328436	USD
	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	-17777	USD
	asmb	Accrued Offering Cost Related To Issuance Of Common Stock AccruedOfferingCostRelatedToIssuanceOfCommonStock	748058	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	32591164	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	7951257	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	20133000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	17165332	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-12458164	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	9211912	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	48070080	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3235908	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	748058	USD
	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	202502	USD
CY2017Q1	us-gaap	Licenses Revenue LicensesRevenue	50000000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4854373	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4114861	shares
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	27287602	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9610	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	473056	USD
CY2017Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	39132524	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	4152931	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	4413	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	29289584	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	140769	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	33442515	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	145182	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	409285	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	409285	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	277428	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	194598	USD
CY2016Q2	us-gaap	Depreciation Depreciation	18000	USD
CY2017Q2	us-gaap	Depreciation Depreciation	51000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2585127	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2884000	USD
CY2017Q2	asmb	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	2771227	USD
CY2016Q4	asmb	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	916674	USD
CY2017Q2	asmb	Accured General And Administrative Expenses Current AccuredGeneralAndAdministrativeExpensesCurrent	638895	USD
CY2016Q4	asmb	Accured General And Administrative Expenses Current AccuredGeneralAndAdministrativeExpensesCurrent	710412	USD
	asmb	Accrued Offering Cost Related To Issuance Of Common Stock AccruedOfferingCostRelatedToIssuanceOfCommonStock	0	USD
CY2017Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	310298	USD
CY2016Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	241737	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	700000	USD
CY2017Q2	asmb	Future Stock Based Compensation Expense Total FutureStockBasedCompensationExpenseTotal	11236771	USD
CY2017Q2	asmb	Future Stock Based Compensation Expense Current FutureStockBasedCompensationExpenseCurrent	4648866	USD
CY2017Q2	asmb	Future Stock Based Compensation Expense Year Two FutureStockBasedCompensationExpenseYearTwo	4775098	USD
CY2017Q2	asmb	Future Stock Based Compensation Expense Year Three FutureStockBasedCompensationExpenseYearThree	1355710	USD
CY2017Q2	asmb	Future Stock Based Compensation Expense Year Four FutureStockBasedCompensationExpenseYearFour	441243	USD
CY2017Q2	asmb	Futurestockbasedcompensationexpenseyearfive Futurestockbasedcompensationexpenseyearfive	15854	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2017Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11200000	USD
	asmb	Sharebased Compensation Arrangement By Sharebased Payment Award Forfeiture Rate SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitureRate	0	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3235908	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2977993	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2011261	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1518138	USD
CY2017Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	16909	shares
CY2017Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2016Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	ASSEMBLY BIOSCIENCES, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001426800
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	ASMB
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17364439	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	800000	USD
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17360689	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17246754	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17246754	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17360689	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 26.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 26.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.2pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Significant estimates inherent in the preparation of the accompanying financial statements include recoverability and useful lives (indefinite or finite) of intangible assets, assessment of impairment of goodwill, and the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters. In addition, with the Company entering into the Collaboration Agreement, the Company believes its condensed consolidated financial statements are also impacted by the following accounting estimates and judgments: (i) identifying deliverables under collaboration agreements involving multiple elements and determining whether such deliverables are separable from other aspects of the contractual relationship; (ii) estimating the selling price of deliverables for the purpose of allocating arrangement consideration for revenue recognition; and (iii) estimating the periods over which the allocated consideration for deliverables is recognized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.2pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	39267533	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10173	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	145182	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-69513	USD
CY2017Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	800000	shares
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-69513	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	125934	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	57437	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	57437	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	183371	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	183371	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13668377	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10152200	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27598970	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21140758	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-69513	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Reimbursement Revenue ReimbursementRevenue	1100000	USD
	asmb	Deferred Revenueamortization Period Over Service Tenure DeferredRevenueamortizationPeriodOverServiceTenure	P10Y
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1113759	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Revenue Recognition Milestone Method Description RevenueRecognitionMilestoneMethodDescription	the Company is eligible to receive up to approximately $630 million in payments related to seven development milestones and up to approximately $2.15 billion in payments related to 12 commercial development and sales milestones in connection with the successful development and commercialization of licensed compounds for up to six different indications
CY2017Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2359311	USD
CY2016Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	0	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	3043680	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	0	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1113759	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD

Files In Submission

Name	View Source	Status
0001144204-17-041660-index-headers.html	Edgar Link	pending
0001144204-17-041660-index.html	Edgar Link	pending
0001144204-17-041660.txt	Edgar Link	pending
0001144204-17-041660-xbrl.zip	Edgar Link	pending
asmb-20170630.xml	Edgar Link	completed
asmb-20170630.xsd	Edgar Link	pending
asmb-20170630_cal.xml	Edgar Link	unprocessable
asmb-20170630_def.xml	Edgar Link	unprocessable
asmb-20170630_lab.xml	Edgar Link	unprocessable
asmb-20170630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v472206_10q.htm	Edgar Link	pending
v472206_ex10-1.htm	Edgar Link	pending
v472206_ex10-2.htm	Edgar Link	pending
v472206_ex10-3.htm	Edgar Link	pending
v472206_ex31-1.htm	Edgar Link	pending
v472206_ex31-2.htm	Edgar Link	pending
v472206_ex32-1.htm	Edgar Link	pending
v472206_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASMB
Assembly Biosciences Inc Stock $asmb

2017 Q3 Form 10-Q Financial Statement

#000114420417041660 Filed on August 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASMB Assembly Biosciences Inc Stock $asmb

2017 Q3 Form 10-Q Financial Statement

#000114420417041660 Filed on August 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASMB
Assembly Biosciences Inc Stock $asmb